feed,title,long_url,short_url
🔐MarketWatch,Novo Nordisk to file for regulatory approval of semaglutide 2.4 mg in U.S. and EU in 2023,http://www.marketwatch.com/tools/quotes/quotes.asp?symb=NOVO.B&siteid=rss,https://da.gd/nJNd2L
